An interview with Maciej Wieczorek in

President of the Board of Celon Pharma S.A. was a guest of the programme Profit. He answered Agniszka Zaręba’s questions on the company’s results for the first half of 2017, on its presence in international markets and the strategy of global commercialisation of the company’s innovative portfolio. We invite you to view the video.

Celon Pharma S.A. with a poster session at ESMO 2017

Poster Design and development of potent E1 ubiquitin activating enzyme inhibitor, CPL-410-005, as novel anticancer therapy – Presented by the leader of the Oncology research team, Aleksandra Stańczak MD at this year’s largest cancer treatment conference. The European Society of Medical Oncology Meeting was held on 9-12 September.  It was participated by 24 thousand participants from 131Read more »

Celon Pharma S.A. receives a construction permit for its Research and Development Centre in Kazuń Nowy.

Celon Pharma S.A. received the final decision on the approval of the construction project and granting the Company a building permit for the construction of its Research and Development Centre located in Kazuń Nowy. The total cost of building and equipping the Research and Development Centre with specialised laboratory equipment (without taking into account theRead more »

Celon Pharma S.A. Finalised an agreement with Plexus Ventures

In line with the contractual provisions, Plexus Ventures will develop a strategy for development of drug candidates and will organise meetings with potential partners. If significant clinical progress is obtained and the parties agree on the development strategy for the drug(s), Plexus Ventures will take steps to obtain partners for the development or licensees, orRead more »

Celon Pharma S.A. received a positive assessment and funding recommendation from the National Centre for Research and Development (NCBiR) for 3 projects of developing innovative medicinal products

The applications where subject to a full, two-stage expert assessment and were selected from among a total of 23 submitted projects applying for co-funding from the InnoNeuroPharm programme. Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.:  Sector-specific programmes are very important tools for supporting research and development activity in the entire industry inRead more »